Compounds > nsc 716970
Page last updated: 2024-12-11

nsc 716970

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

centanamycin: a potent antimalarial and transmission-blocking DNA-binding agent inspired from ( )-duocarmycin SA that lacks a stereocenter; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

AS-I-145 : An indolecarboxamide obtained by the formal condensation of the carboxy group of 5,6,7-trimethoxyindole-2-carboxylic acid with the 2-amino group of 1-(2-chloroethyl)-2,4-diaminonaphthalene. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9825161
CHEMBL ID192069
CHEBI ID82669
SCHEMBL ID5733476
MeSH IDM0575868

Synonyms (22)

Synonym
n-[4-amino-1-(2-chloroethyl)naphthalen-2-yl]-5,6,7-trimethoxy-1h-indole-2-carboxamide
nsc-716970
413577-16-9
nsc716970
1h-indole-2-carboxamide,6,7-trimethoxy-
chebi:82669 ,
centanamycin
CHEMBL192069
SCHEMBL5733476
4-(2-chloroethyl)-3-(5,6,7-trimethoxyindole-2-carboxamido)-1-naphthylamine
MNFPZBOQEWMBOK-UHFFFAOYSA-N
as-i-145
n-[4-amino-1-(2-chloroethyl)-2-naphthyl]-5,6,7-trimethoxy-1h-indole-2-carboxamide
DTXSID30431368
as-1145
Q27156187
as-i 145
866dfl3tmf ,
unii-866dfl3tmf
n-(4-azanyl-1-(2-chloroethyl)naphthalen-2-yl)-5,6,7-trimethoxy-1h-indole-2-carboxamide
1h-indole-2-carboxamide, n-(4-amino-1-(2-chloroethyl)-2-naphthalenyl)-5,6,7-trimethoxy-
nsc 716970
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
indolecarboxamide
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID251530Concentration required to kill 50% of human K-562 leukemia cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID248153The concentration required for inhibiting the growth of the murine B16-F0 melanoma cells by 50%2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251541Concentration required to kill 50% of human SF-539 CNS cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251575Concentration required to kill 50% of human EKVX non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID514352Antimicrobial activity against promastigotes of Leishmania donovani assessed as inhibition of cell proliferation after 72 hrs by alamar blue assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.
AID514253Binding affinity to pUC18 DNA assessed as DNA alkylating activity after 5 hrs by thermal cleavage assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.
AID251567Concentration required to kill 50% of human DU-145 prostate cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251577Concentration required to kill 50% of human HOP-92 non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251564Concentration required to kill 50% of human HCC2998 colon cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251578Concentration required to kill 50% of human NCI-H23 non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID514355Antimicrobial activity against promastigotes of Leishmania mexicana assessed as inhibition of cell proliferation after 72 hrs by alamar blue assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.
AID248170The concentration required for inhibiting the growth of the murine P815 mastocytoma cells by 50%2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251569Concentration required to kill 50% of human OVCAR-4 ovarian cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251561Concentration required to kill 50% of human PC-3 prostate cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251549Concentration required to kill 50% of human RPMI-8226 leukemia cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251582Concentration required to kill 50% of human A549/ATCC non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251548Concentration required to kill 50% of human MCF-7 breast cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251565Concentration required to kill 50% of human Hs 578.T breast cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID514254Cytotoxicity against mouse L1210 cells after 3 days by MTT assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.
AID514353Antimicrobial activity against procyclic form of Trypanosoma brucei 427 assessed as inhibition of cell proliferation after 72 hrs by alamar blue assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.
AID514354Antimicrobial activity against Plasmodium falciparum infected in human erythrocytes assessed as growth inhibition2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.
AID251543Concentration required to kill 50% of human SK-MEL-5 melanoma cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251547Concentration required to kill 50% of human A-498 renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251542Concentration required to kill 50% of human SK-MEL-2 melanoma cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251581Concentration required to kill 50% of human NCI-H522 non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251545Concentration required to kill 50% of human SNB-75 CNS cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251551Concentration required to kill 50% of human SN12C renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251535Concentration required to kill 50% of human HT-29 colon cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251555Concentration required to kill 50% of human HCT-15 colon cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251553Concentration required to kill 50% of human UO-31 renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251554Concentration required to kill 50% of human CAKI-1 renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID709182Antimalarial activity against Plasmodium chabaudi infected rat malaria model2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID709181Antimalarial activity against Plasmodium berghei infected in mosquitoes assessed as reduction in number of oocysts2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID709186Antimalarial activity against Plasmodium falciparum gametocytes2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID251556Concentration required to kill 50% of human MDA-N breast cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251559Concentration required to kill 50% of human BT-549 breast cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251536Concentration required to kill 50% of human KM12 colon cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251531Concentration required to kill 50% of human MOLT-4 leukemia cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID709180Antimalarial activity against Plasmodium berghei infected in mosquitoes assessed as reduction in number of sporozoites2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate.
AID251533Concentration required to kill 50% of human UACC-62 melanoma cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251583Concentration required to kill 50% of human NCI-H322M non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251570Concentration required to kill 50% of human OVCAR-5 ovarian cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251580Concentration required to kill 50% of human NCI-H460 non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251579Concentration required to kill 50% of human NCI-H226 non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251573Concentration required to kill 50% of human NCI/ADR-RES breast cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251532Concentration required to kill 50% of human U-251 CNS cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID248128The concentration required for inhibiting the growth of the murine L1210 leukemia cells by 50%2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251552Concentration required to kill 50% of human TK-10 renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251576Concentration required to kill 50% of human HOP-62 non-small cell lung cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251566Concentration required to kill 50% of human IGROV1 ovarian cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251534Concentration required to kill 50% of human ACHN renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251540Concentration required to kill 50% of human SF-295 CNS cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID276044Cytotoxicity against mouse P815 cells after 3 days2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
DNA interstrand crosslinking agents: synthesis, DNA interactions, and cytotoxicity of dimeric achiral seco-amino-CBI and conjugates of achiral seco-amino-CBI with pyrrolobenzodiazepine (PBD).
AID251537Concentration required to kill 50% of human LOX IMVI melanoma cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251574Concentration required to kill 50% of human MDA-MB-231/ATCC breast cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251546Concentration required to kill 50% of human 786-0 renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID248416The concentration required for inhibiting the growth of the human K562 chronic myeloid leukemia cells by 50%2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251563Concentration required to kill 50% of human COLO 205 colon cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251550Concentration required to kill 50% of human SK-MEL-28 melanoma cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251544Concentration required to kill 50% of human SNB-19 CNS cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251539Concentration required to kill 50% of human SF-268 CNS cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251560Concentration required to kill 50% of human HCT116 colon cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251571Concentration required to kill 50% of human OVCAR-8 ovarian cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251529Concentration required to kill 50% of human HL-60 leukemia cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251562Concentration required to kill 50% of human RXF 393 renal cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251557Concentration required to kill 50% of human SW-620 colon cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251568Concentration required to kill 50% of human OVCAR-3 ovarian cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID514255Cytotoxicity against mouse B16F0 cells after 3 days by MTT assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation.
AID251538Concentration required to kill 50% of human MALME-3M melanoma cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251572Concentration required to kill 50% of human SK-OV-3 ovarian cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
AID251558Concentration required to kill 50% of human T-47D breast cancer cells2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3,7-bis(dimethylamino)phenothiazin-5-ium
3,7-bis(dimethylamino)phenothiazin-5-ium : An organic cation that is phenothiazin-5-ium substituted by dimethylamino groups at positions 3 and 7. The chloride salt is the histological dye 'methylene blue'.		2.0710organic cation
primaquine
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.		2.0710aminoquinoline;
aromatic ether;
N-substituted diamine		antimalarial
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.0410pyrrole;
secondary amine
pyronaridine
[no description available]		2.0710aminoquinoline
tafenoquine
tafenoquine : A racemate comprising equimolar amounts of (R)- and (S)-tafenoquine.. N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine : An aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group.		2.0710(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound
duocarmycin sa
duocarmycin SA: structure similar to CC-1065 and yatakemycin, composed of a pyrrolo-indole plus an indole; isolated from Streptomyces		2.0410
sjg 136
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione): structure in first source		2.0310
cc 1065
CC 1065: from Streptomyces zelensis; structure in second sourc		2.4420
epoxomicin
[no description available]		2.0710morpholines;
tripeptide		proteasome inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Malignant Melanoma
[description not available]		02.0510
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.0510
Infections, Plasmodium
[description not available]		02.0410
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.0410
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0410